相似文献
1
Cancer subclonal genetic architecture as a key to personalized medicine.
Neoplasia. 2013 Dec;15(12):1410-20. doi: 10.1593/neo.131972.
2
The Future of Precision Medicine in Oncology.
Clin Lab Med. 2016 Sep;36(3):557-73. doi: 10.1016/j.cll.2016.05.003.
3
Developing precision medicine in a global world.
Clin Cancer Res. 2014 Mar 15;20(6):1419-27. doi: 10.1158/1078-0432.CCR-14-0091.
4
Molecular Pathology: A Requirement for Precision Medicine in Cancer.
Oncol Res Treat. 2016;39(12):804-810. doi: 10.1159/000453085. Epub 2016 Nov 25.
5
One mouse, one patient paradigm: New avatars of personalized cancer therapy.
Cancer Lett. 2014 Mar 1;344(1):1-12. doi: 10.1016/j.canlet.2013.10.010. Epub 2013 Oct 22.
6
[Precision Oncology: Approaching the Target].
Dtsch Med Wochenschr. 2017 Nov;142(22):1637. doi: 10.1055/s-0043-114489. Epub 2017 Oct 27.
7
[New directions in biomarker research, drug development and personalized medicine].
Magy Onkol. 2013 Mar;57(1):5-10. Epub 2013 Feb 10.
8
[Translational research - towards personalized medicine].
Nihon Yakurigaku Zasshi. 2013 Mar;141(3):122-5. doi: 10.1254/fpj.141.122.
9
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Lancet Oncol. 2015 Oct;16(13):1324-34. doi: 10.1016/S1470-2045(15)00188-6. Epub 2015 Sep 3.
10
Precision cancer medicine: the future is now, only better.
Am Soc Clin Oncol Educ Book. 2014:61-9. doi: 10.14694/EdBook_AM.2014.34.61.
引用本文的文献
1
Evaluation of the Anti-Inflammatory and Anti-Oxidative Effects of Therapeutic Human Lactoferrin Fragments.
Front Bioeng Biotechnol. 2021 Nov 30;9:779018. doi: 10.3389/fbioe.2021.779018. eCollection 2021.
2
Sequential Salinomycin Treatment Results in Resistance Formation through Clonal Selection of Epithelial-Like Tumor Cells.
Transl Oncol. 2014 Dec;7(6):702-11. doi: 10.1016/j.tranon.2014.09.002.
3
PACE4-based molecular targeting of prostate cancer using an engineered ⁶⁴Cu-radiolabeled peptide inhibitor.
Neoplasia. 2014 Aug;16(8):634-43. doi: 10.1016/j.neo.2014.07.010.
本文引用的文献
1
Combining molecular targeted drugs to inhibit both cancer cells and activated stromal cells in gastric cancer.
Neoplasia. 2013 Dec;15(12):1391-9. doi: 10.1593/neo.131668.
2
Regulation of metformin response by breast cancer associated gene 2.
Neoplasia. 2013 Dec;15(12):1379-90. doi: 10.1593/neo.131434.
3
Tumor evolution and intratumor heterogeneity of an oropharyngeal squamous cell carcinoma revealed by whole-genome sequencing.
Neoplasia. 2013 Dec;15(12):1371-8. doi: 10.1593/neo.131400.
4
N-Myc differentially regulates expression of MXI1 isoforms in neuroblastoma.
Neoplasia. 2013 Dec;15(12):1363-70. doi: 10.1593/neo.11606.
5
Synthetic lethality screen identifies RPS6KA2 as modifier of epidermal growth factor receptor activity in pancreatic cancer.
Neoplasia. 2013 Dec;15(12):1354-62. doi: 10.1593/neo.131660.
6
Quantitative analysis of [11C]-erlotinib PET demonstrates specific binding for activating mutations of the EGFR kinase domain.
Neoplasia. 2013 Dec;15(12):1347-53. doi: 10.1593/neo.131666.
7
Inflammatory factors of the tumor microenvironment induce plasticity in nontransformed breast epithelial cells: EMT, invasion, and collapse of normally organized breast textures.
Neoplasia. 2013 Dec;15(12):1330-46. doi: 10.1593/neo.131688.
8
PTEN phosphatase-independent maintenance of glandular morphology in a predictive colorectal cancer model system.
Neoplasia. 2013 Nov;15(11):1218-30. doi: 10.1593/neo.121516.
9
Alternative lengthening of telomeres: recurrent cytogenetic aberrations and chromosome stability under extreme telomere dysfunction.
Neoplasia. 2013 Nov;15(11):1301-13. doi: 10.1593/neo.131574.
10
ETV6/RUNX1 induces reactive oxygen species and drives the accumulation of DNA damage in B cells.
Neoplasia. 2013 Nov;15(11):1292-300. doi: 10.1593/neo.131310.
Zotero 插件